SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Perspectives in Vascular Surgery and Endovascular Therapy
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sumpio, B. E.
Right arrow Articles by Aruny, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sumpio, B. E.
Right arrow Articles by Aruny, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cilostazol Inhibits Leukocyte Integrin Mac-1, Leading to a Potential Reduction in Restenosis After Coronary Stent Implantation

Bauer E. Sumpio, MD, PhD

John Aruny, MD

Sections of Vascular Surgery and Interventional Radiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520.

The study was conducted to determine if ci'ostazol inhibits leukocyte MVac-i, leading to prevention of poststent restenosis. C lostazol inhibits platelet phosphodiesterase III as well as u-granule release of P-selection in platelets, which have a key role in the upregulation of leucocyte Mac1. The activation and upregulation of NMac-i .s key in the mechanism of restenosis after coronary stenting. Consecutive patients (n = 70) undergoing coronary stenting were randomly assigned to either cilostazol or ticlopidine before stent placement. The 34 patients in the cilostazol group had a lower rate of restenosis than tne 22 patients in the ticlopidire group. Cilostazol suppressed stent-induced increases .n platelet. P selection expression and an increase in neutrophil Mac-I expression. The authors concluded that cilostazol may reduce the rate of restenosis after coronary stent implantation.

Key Words: stent restenosis • cilostazol • platelets

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 17, No. 3, 265-267 (2005)
DOI: 10.1177/153100350501700317
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement